Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer

Lung Cancer

Volumn 59, Issue 1, 2008, Pages 95-104

  Lee, Hyun Woo ^a   Han, Jae Ho ^a   Kim, Jang Hee ^a   Lee, Myoung Hee ^a   Jeong, Seong Hyun ^a   Kang, Seok Yun ^a   Choi, Jin Hyuk ^a   Oh, Young Taek ^a   Park, Kwang Joo ^a   Hwang, Sung Chul ^a   Sheen, Seung Soo ^a   Lim, Ho Yeong ^b  

^a Ajou University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

Author keywords

Chemotherapy; ERCC1; Prognosis; Small cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; IFOSFAMIDE; IRINOTECAN; PLATINUM; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CORRELATION ANALYSIS; EXCISION REPAIR; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEX DIFFERENCE; TUMOR BIOPSY;

ADULT; AGED; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, SMALL CELL; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 37549056534     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.07.023     Document Type: Article

References (40)

1. Jackman D.M., and Johnson B.E. Small-cell lung cancer. Lancet 366 (2005) 1385-1396
2. Sandler A.B. Chemotherapy for small cell lung cancer. Semin Oncol 30 (2003) 9-25
3. Spira A., and Ettinger D.S. Multidisciplinary management of lung cancer. N Engl J Med 350 (2004) 379-392
4. Shin H.-R., Jung K.-W., Won Y.-J., and Park J.-G. 2002 Annual report of the Korea Central Cancer Registry: based on registered data from 139 hospitals. Cancer Research and Treatment 36 (2004) 103-114
5. Dingemans A.M., Witlox M.A., Stallaert R.A., van der Valk P., Postmus P.E., and Giaccone G. Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer. Clin Cancer Res 5 (1999) 2048-2058
6. Viktorsson K., De Petris L., and Lewensohn R. The role of p53 in treatment responses of lung cancer. Biochem Biophys Res Commun 331 (2005) 868-880
7. Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 3 4 (1973) 31-42
8. Miller A.B., Hoogstraten B., Staquet M., and Winkler A. Reporting results of cancer treatment. Cancer 47 (1981) 207-214
9. Kaplan E., and Meier P. Non-parametric estimations from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
10. Cox D.R. Regression model and life-tables. J R Stat Soc Ser 34 (1972) 187-220
11. Reed E. ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res 11 (2005) 6100-6102
12. Fulda S., and Debatin K.M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25 (2006) 4798-4811
13. Ling C.C., Guo M., Chen C.H., and Deloherey T. Radiation-induced apoptosis: effects of cell age and dose fractionation. Cancer Res 55 (1995) 5207-5212
14. D'Amico D., Carbone D., Mitsudomi T., Nau M., Fedorko J., Russell E., et al. High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. Oncogene 7 (1992) 339-346
15. Gemba K., Ueoka H., Kiura K., Tabata M., and Harada M. Immunohistochemical detection of mutant p53 protein in small-cell lung cancer: relationship to treatment outcome. Lung Cancer 29 (2000) 23-31
16. Kaiser U., Schilli M., Haag U., Neumann K., Kreipe H., Kogan E., et al. Expression of bcl-2-protein in small cell lung cancer. Lung Cancer 15 (1996) 31-40
17. Kawasaki M., Nakanishi Y., Kuwano K., Takayama K., Kiyohara C., and Hara N. Immunohistochemically detected p53 and P-glycoprotein predict the response to chemotherapy in lung cancer. Eur J Cancer 34 (1998) 1352-1357
18. Maitra A., Amirkhan R.H., Saboorian M.H., Frawley W.H., and Ashfaq R. Survival in small cell lung carcinoma is independent of Bcl-2 expression. Hum Pathol 30 (1999) 712-717
19. Paik K.H., Park Y.H., Ryoo B.Y., Yang S.H., Lee J.C., Kim C.H., et al. Prognostic value of immunohistochemical staining of p53, bcl-2, and Ki-67 in small cell lung cancer. J Korean Med Sci 21 (2006) 35-39
20. Rodriguez-Salas N., Palacios J., Moreno G., de Castro J., Gonzalez-Baron M., and Gamallo C. Correlation of p53 oncoprotein expression with chemotherapy response in small cell lung carcinomas. Lung Cancer 34 (2001) 67-74
21. Takayama K., Ogata K., Nakanishi Y., Yatsunami J., Kawasaki M., and Hara N. Bcl-2 expression as a predictor of chemosensitivities and survival in small cell lung cancer. Cancer J Sci Am 2 (1996) 212-216
22. Zereu M., Vinholes J.J., and Zettler C.G. p53 and Bcl-2 protein expression and its relationship with prognosis in small-cell lung cancer. Clin Lung Cancer 4 (2003) 298-302
23. Ben-Ezra J.M., Kornstein M.J., Grimes M.M., and Krystal G. Small cell carcinomas of the lung express the Bcl-2 protein. Am J Pathol 145 (1994) 1036-1040
24. Ikegaki N., Katsumata M., Minna J., and Tsujimoto Y. Expression of bcl-2 in small cell lung carcinoma cells. Cancer Res 54 (1994) 6-8
25. Reeve J.G., Xiong J., Morgan J., and Bleehen N.M. Expression of apoptosis-regulatory genes in lung tumour cell lines: relationship to p53 expression and relevance to acquired drug resistance. Br J Cancer 73 (1996) 1193-1200
26. Ceppi P., Volante M., Novello S., Rapa I., Danenberg K., Danenberg P., et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 17 (2006) 1818-1825
27. Olaussen K.A., Dunant A., Fouret P., Brambilla E., Andre F., Haddad V., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355 (2006) 983-991
28. Rosell R., Taron M., Ariza A., Barnadas A., Mate J.L., Reguart N., et al. Molecular predictors of response to chemotherapy in lung cancer. Semin Oncol 31 (2004) 20-27
29. Reardon J.T., Vaisman A., Chaney S.G., and Sancar A. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res 59 (1999) 3968-3971
30. Niedernhofer L.J., Odijk H., Budzowska M., van Drunen E., Maas A., Theil A.F., et al. The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol 24 (2004) 5776-5787
31. Wachters F.M., Wong L.S., Timens W., Kampinga H.H., and Groen H.J. ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. Lung Cancer 50 (2005) 211-219
32. Simon G.R., Sharma S., Cantor A., Smith P., and Bepler G. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 127 (2005) 978-983
33. Dabholkar M., Vionnet J., Bostick-Bruton F., Yu J.J., and Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 94 (1994) 703-708
34. Joshi M.B., Shirota Y., Danenberg K.D., Conlon D.H., Salonga D.S., Herndon II J.E., et al. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 11 (2005) 2215-2221
35. Lord R.V., Brabender J., Gandara D., Alberola V., Camps C., Domine M., et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8 (2002) 2286-2291
36. Metzger R., Leichman C.G., Danenberg K.D., Danenberg P.V., Lenz H.J., Hayashi K., et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16 (1998) 309-316
37. Rosell R., Danenberg K.D., Alberola V., Bepler G., Sanchez J.J., Camps C., et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 10 (2004) 1318-1325
38. Shirota Y., Stoehlmacher J., Brabender J., Xiong Y.P., Uetake H., Danenberg K.D., et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19 (2001) 4298-4304
39. Murray D., and Rosenberg E. The importance of the ERCC1/ERCC4[XPF] complex for hypoxic-cell radioresistance does not appear to derive from its participation in the nucleotide excision repair pathway. Mutat Res 364 (1996) 217-226
40. Murray D., Vallee-Lucic L., Rosenberg E., and Andersson B. Sensitivity of nucleotide excision repair-deficient human cells to ionizing radiation and cyclophosphamide. Anticancer Res 22 (2002) 21-26